These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 30701022)
21. RET fusion as a novel driver of medullary thyroid carcinoma. Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157 [TBL] [Abstract][Full Text] [Related]
22. Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm. Jarzab B; Krajewska J Eur Endocrinol; 2014 Aug; 10(2):145-150. PubMed ID: 29872479 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. Trimboli P; Castellana M; Virili C; Giorgino F; Giovanella L Front Endocrinol (Lausanne); 2018; 9():224. PubMed ID: 29774010 [TBL] [Abstract][Full Text] [Related]
28. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560 [TBL] [Abstract][Full Text] [Related]
29. Update on the cytologic and molecular features of medullary thyroid carcinoma. Pusztaszeri MP; Bongiovanni M; Faquin WC Adv Anat Pathol; 2014 Jan; 21(1):26-35. PubMed ID: 24316908 [TBL] [Abstract][Full Text] [Related]
30. Cabozantinib for the treatment of advanced medullary thyroid cancer. Nagilla M; Brown RL; Cohen EE Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465 [TBL] [Abstract][Full Text] [Related]
31. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Dadu R; Hu MN; Grubbs EG; Gagel RF Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392 [TBL] [Abstract][Full Text] [Related]
32. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer. Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667 [TBL] [Abstract][Full Text] [Related]
33. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558 [TBL] [Abstract][Full Text] [Related]
34. New drugs for medullary thyroid cancer: new promises? Spitzweg C; Morris JC; Bible KC Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870 [TBL] [Abstract][Full Text] [Related]
35. Managing tyrosine kinase inhibitors side effects in thyroid cancer. Krajewska J; Paliczka-Cieslik E; Jarzab B Expert Rev Endocrinol Metab; 2017 Mar; 12(2):117-127. PubMed ID: 30063430 [TBL] [Abstract][Full Text] [Related]